Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): a phase 2 study evaluating an individualized treatment strategy for metastatic disease

The 1-year and median overall survivals (mOS) of advanced gastroesophageal adenocarcinomas (GEA) are ~50% and <12 months. Baseline spatial and temporal molecular heterogeneity of targetable alterations may be a cause of failure of targeted/immunooncologic therapies. This heterogeneity, coupled wi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Discov
Main Authors: Catenacci, Daniel V.T., Moya, Stephanie, Lomnicki, Samantha, Chase, Leah M., Peterson, Bryan F., Reizine, Natalie, Alpert, Lindsay, Setia, Namrata, Xiao, Shu-Yuan, Hart, John, Siddiqui, Uzma D., Hogarth, D. Kyle, Eng, Oliver S., Turaga, Kiran, Roggin, Kevin, Posner, Mitchell C., Chang, Paul, Narula, Sunil, Rampurwala, Murtuza, Ji, Yuan, Karrison, Theodore, Liao, Chih-Yi, Polite, Blase N., Kindler, Hedy L.
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7858231/
https://ncbi.nlm.nih.gov/pubmed/33234578
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-20-1408
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados